About Graviti Pharmaceuticals Private Limited
Data last updated:
Graviti Pharmaceuticals Private Limited is a private limited company based in Hyderabad, Telangana, India, a subsidiary of Yashoda Healthcare Services Private Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 27 December 2012 and has been in existence for over 14 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24232TG2012PTC085058. Its GSTIN is 36AALCA2773N1Z5 (Telangana). The company holds 3 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹50 Cr and a paid-up capital of ₹49 Cr. It was formerly known as Abhayam Pharmaceuticals Private Limited. It is led by directors including Dheeraj Kumar Gorukanti (Managing Director) and Jaganmohan Rao Boinapalli.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Hyderabad, Telangana.
As per the financials filed for FY 2025, the company reported a revenue of ₹543.75 Cr, a growth of 17% compared to the previous year. For the same year it recorded a net profit of ₹90.4 Cr (net margin 16.6%) and EBITDA of ₹148.23 Cr (EBITDA margin 27.3%). Revenue has grown at a compounded annual rate (CAGR) of 37% over three years and 21% over five years.
The company has about 841 employees on its provident fund (EPFO) records. Its group structure includes 3 subsidiaries.
The company is associated with 1 brand: Graviti Pharmaceuticals. As per MCA filings, the company has open charges of ₹327 Cr and satisfied charges of ₹405.25 Cr on record. The company has 5 deals on record (3 secondary share transfers, 2 funding rounds), with disclosed funding of ₹48.99 Cr; the latest was in December 2023. Its 7 peer companies in the Pharma industry (Contract Research, Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 2 smaller; the largest is Bajaj Healthcare Limited with revenue of ₹562.01 Cr. The company has 10 MSME Form 1 returns on record between 2019 and 2024, listing 276 overdue payments to 60 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website gravitipharma.com.
Company details
CIN history
Graviti Pharmaceuticals has one previous CIN (Corporate Identification Number): U24232AP2012PTC085058. The current CIN is U24232TG2012PTC085058, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232TG2012PTC085058 | Current |
| U24232AP2012PTC085058 | Previous |
Contact details
Graviti Pharmaceuticals Private Limited's registered office is in Hyderabad, Telangana. Its website is gravitipharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressHouse No. 8 – 2 – 248/1/7/64 Plot No.64 Nagarjuna Co – Operative Housing Society, Punjagutta, Hyderabad, Telangana, India – 500082
- IndustryPharma, Drug Formulation & Development, Pharma Contract R&D
To see the full contact details of Graviti Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Graviti Pharmaceuticals operates one associated brand: Graviti Pharmaceuticals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical manufacturing and distribution of generics in India and globally. | gravitipharma.com |
Business activity
The main business activity of Graviti Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Graviti Pharmaceuticals Private Limited, buy the company report.
Financials of Graviti Pharmaceuticals Private Limited
FY 2025 filings availableGraviti Pharmaceuticals Private Limited reported revenue of ₹543.75 Cr (up 17% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 21% over five years, including 17% growth in the latest year. EBITDA rose 63% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹148.23 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹90.4 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 27.3% | ||||
| Net Profit Margin | 16.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Graviti Pharmaceuticals Private Limited, buy the company report.
Board of directors of Graviti Pharmaceuticals Private Limited
Graviti Pharmaceuticals has 3 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Jaganmohan Rao Boinapalli Also directs: Infinity Pharma & Drugs Private Limited, Plazma Systems Private Limited, Graviti Living Spaces (India) Private Limited and 2 more | Director | 24 Mar 2025 | 1 Years 7 Months | Current |
| Suguna Raman | Director | 27 Dec 2012 | 13 Years 10 Months | Current |
| Dheeraj Kumar Gorukanti Also directs: Infinity Pharma & Drugs Private Limited, Plazma Systems Private Limited, Fyzks Inspection Systems Private Limited and 5 more | Managing Director | 27 Dec 2012 | 13 Years 10 Months | Current |
Peer comparison
Graviti Pharmaceuticals Private Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (Contract Research, Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Bajaj Healthcare Limited | ₹562.01 Cr (FY 2025) | 17.0% | Thane, Maharashtra, India | |||
| G S Pharmbutor Private Limited | ₹561.56 Cr (FY 2025) | 6.0% | Rudrapur, Uttarakhand, India | |||
| Ind Swift Limited | ₹560.24 Cr (FY 2024) | 33.0% | Chandigarh, India | |||
| Shalina Laboratories Private Limited | ₹551.12 Cr (FY 2023) | -1.0% | Mumbai, Maharashtra, India | |||
| German Remedies Pharmaceuticals Private Limited | ₹546.98 Cr (FY 2025) | 9.0% | Ahmedabad, Gujarat, India | |||
| Graviti Pharmaceuticals Private Limitedthis company | ₹543.75 Cr (FY 2025) | ₹90.4 Cr | 16.6% | 17.0% | 841 | Hyderabad, Telangana, India |
| Kusum Healthcare Private Limited | ₹537.89 Cr (FY 2025) | 10.0% | New Delhi, Delhi, India | |||
| Unison Pharmaceuticals Private Limited | ₹537.1 Cr (FY 2025) | 23.0% | Ahmedabad, Gujarat, India |
To see the full peer comparison of Graviti Pharmaceuticals Private Limited, buy the company report.
Auditor
Graviti Pharmaceuticals Private Limited is audited by Visweswara Rao & Associates for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Visweswara Rao & Associates | FY 2024 | 005774S |
Shareholding
The shareholding of Graviti Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Graviti Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 15 Oct 2024 | 100998039 | Hdfc Bank Limited | ₹179 Cr | Open | |
| 26 Sep 2023 | 100793871 | Others | ₹148 Cr | Open | |
| 22 Sep 2017 | 100132716 | Axis Bank Limited | ₹245.25 Cr | Satisfied | |
| 31 Mar 2015 | 10566842 | Axis Bank Limited | ₹160 Cr | Satisfied |
To see the full charge records of Graviti Pharmaceuticals Private Limited, buy the company report.
Total charge records: 4 View all charges
Deals & funding
Graviti Pharmaceuticals Private Limited has 5 deals on record (3 secondary share transfers, 2 funding rounds), with disclosed funding of ₹48.99 Cr; the latest was in December 2023.
Deals on record (5 of 5)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Dec 2023 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: Yashoda Healthcare Services Limited |
| Jun 2022 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: Yashoda Healthcare Services Limited |
| Apr 2017 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Nov 2015 | Funding round | ₹3 Cr | Investors: Yashoda Healthcare Services Limited |
| Jun 2014 | Funding round | ₹45.99 Cr | Investors: Yashoda Healthcare Services Limited , 2 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Graviti Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
Credit ratings & regulatory alerts
Graviti Pharmaceuticals Private Limited was last rated by Care on 03 Jan 2023.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 03 Jan 2023 |
To see the full credit ratings and regulatory alerts of Graviti Pharmaceuticals Private Limited, buy the company report.
MSME payment delays
Graviti Pharmaceuticals Private Limited has 10 MSME Form 1 returns on record between 2019 and 2024, listing 276 overdue payments to 60 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 60)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Sai Siri Packaging | |||
| Sreeja Chemicals | |||
| Sotax India Private Limited | |||
| an individual supplier | |||
| Cilicant Private Limited |
To see the full MSME payment records of Graviti Pharmaceuticals Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Graviti Pharmaceuticals has 3 subsidiary companies and 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Daimen Pharma Private Limited | U24290TG2020PTC146071 | |
| Hopped Up Trade Private Limited | U45200TG2013PTC090595 | |
| Graviti Foundation | U85100TG2020NPL146238 |
To see the full group structure of Graviti Pharmaceuticals Private Limited, buy the company report.
Employees & EPFO
Graviti Pharmaceuticals Private Limited has a workforce of 841 employees on its EPFO records as of Sep 01, 2025, across 1 active EPFO establishment.
GST
Graviti Pharmaceuticals has 3 GST registrations: 1 active and 2 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AALCA2773N1Z5 | Telangana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Graviti Pharmaceuticals Private Limited, buy the company report.
Recent activity
Graviti Pharmaceuticals Private Limited has 6 board changes on record since 2012: 3 appointments and 3 cessations. The latest: Jaganmohan Rao Boinapalli ceased to be Additional Director on 29 Sep 2025.
6 earlier events are in the company report.
Frequently asked questions
Graviti Pharmaceuticals is an active private limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 27 December 2012 (14+ years old) and is registered under CIN U24232TG2012PTC085058.
Graviti Pharmaceuticals has 3 current directors:
- Dheeraj Kumar Gorukanti - Managing Director
- Jaganmohan Rao Boinapalli - Director
- Suguna Raman - Director
The latest financial statements of Graviti Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Graviti Pharmaceuticals is 36AALCA2773N1Z5, registered in Telangana. The company has 3 GST registrations in all, of which 1 is active and 2 are cancelled or inactive.
The CIN (Corporate Identification Number) of Graviti Pharmaceuticals is U24232TG2012PTC085058. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Graviti Pharmaceuticals was incorporated on 27 December 2012, making it 14+ years old. It is registered with the Registrar of Companies, Hyderabad.
Graviti Pharmaceuticals has 5 deals on record (3 secondary share transfers, 2 funding rounds), with disclosed funding of ₹48.99 Cr; the latest was in December 2023.
The peers of Graviti Pharmaceuticals by revenue are Bajaj Healthcare Limited, G S Pharmbutor Private Limited, Ind Swift Limited, Shalina Laboratories Private Limited, German Remedies Pharmaceuticals Private Limited and 2 more, all in the Pharma industry (Contract Research, Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Jaganmohan Rao Boinapalli ceased to be Additional Director on 29 Sep 2025. Jaganmohan Rao Boinapalli was appointed as Director on 24 Mar 2025. Ravender Gorukanti Rao ceased to be Director on 13 Mar 2017. Graviti Pharmaceuticals has 6 board changes on record in total.
Graviti Pharmaceuticals has 10 MSME Form 1 returns on record between 2019 and 2024, listing 276 overdue payments to 60 micro and small suppliers. The latest return was filed on 30 Apr 2024.
Graviti Pharmaceuticals can be reached through the website gravitipharma.com. Its registered office is in Hyderabad, Telangana, India.
The registered office of Graviti Pharmaceuticals is at House No. 8 – 2 – 2481764 Plot No.64 Nagarjuna Co – Operative Housing Society, Punjagutta, Hyderabad, Telangana, India – 500082.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
